Vast majority of Part D plan formularies are designed to encourage the use of generic drugs

An estimated $98 billion in Medicare Part D prescription drug spending in 2019, plan sponsors can affect overall retail drug spending in United States.  The plan’s formulary coverage and tier placement influence whether or not a particular drug is affordable and ultimately accessible to patients.  In recent press reports and other evidence suggest that Part D plans are increasingly listing certain generics on nonpreferred tiers (those with higher cost sharing) listing some generics less favorably than brand-name drugs or not including certain generics on the formulary at all. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org